You are here

  • Home
  • Archive
  • Volume 15, Issue 12
  • Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity

Article Text

Article menu
Download PDFPDF
Case Reports: Learning from unexpected outcome (positive or negative)
Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity
  1. Hamza Abrar Mughal1,
  2. Mette T Mouritzen1,2,
  3. Zsuzsanna Takacs-Szabó3 and
  4. Weronika Maria Szejniuk1,2
  1. 1Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
  2. 2Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark
  3. 3Department of Radiology, Aalborg University Hospital, Aalborg, Denmark
  1. Correspondence to Dr Weronika Maria Szejniuk; wszejniuk{at}gmail.com

Abstract

Treatment of induced oligometastatic disease after partial response to systemic antineoplastic therapy in non-small cell lung cancer (NSCLC) remains controversial. The introduction of immune checkpoint inhibitors (ICIs) has revolutionised the treatment of stage IV NSCLC. While ICI combined with chemotherapy (ChT) leads to longer duration of response and higher response rates compared with ChT alone, it can also cause serious adverse events (AEs) resulting in treatment discontinuation. In case of treatment discontinuation due to AEs after partial response to systemic treatment, surgical treatment of residual disease can be considered as it could lead to complete response. We present a case of a patient with stage IV NSCLC who is currently alive without any signs of cancer after partial response to ICI/ChT followed by surgical removal of residual disease.

  • Cancer intervention
  • Lung cancer (oncology)
  • Surgical oncology

https://doi.org/10.1136/bcr-2022-252590

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors HAM: case report data collection, writing, reviewing and editing. MTM: writing, reviewing and editing. ZT-S: radiological evaluation, reviewing and editing. WMS: supervision, writing, reviewing and editing.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.